Key Points
- Sangsangin Investment & Securi sold 433,332 shares of Exicure (NASDAQ:XCUR) on December 8 at an average price of $8.71, generating proceeds of $3,774,321.72 as disclosed in an SEC Form 4.
- The stock opened at $5.32, has a market cap of $33.91 million, reported a -$0.39 EPS last quarter, and carries a consensus Sell rating (Weiss Ratings reissued a "sell (d-)").
- Exicure is an early‑stage biotech developing nucleic acid therapies—including a preclinical SCN9A program for chronic pain—and remains high‑risk with a negative earnings profile and a beta of 4.08.
Exicure, Inc. (NASDAQ:XCUR - Get Free Report) major shareholder Sangsangin Investment & Securi sold 433,332 shares of the firm's stock in a transaction on Monday, December 8th. The stock was sold at an average price of $8.71, for a total transaction of $3,774,321.72. The sale was disclosed in a document filed with the SEC, which is available through this link. Major shareholders that own at least 10% of a company's shares are required to disclose their sales and purchases with the SEC.
Exicure Stock Performance
NASDAQ:XCUR opened at $5.32 on Thursday. The stock has a 50-day simple moving average of $4.60 and a 200 day simple moving average of $5.98. Exicure, Inc. has a one year low of $3.10 and a one year high of $22.99. The company has a market capitalization of $33.91 million, a price-to-earnings ratio of -1.44 and a beta of 4.08.
Exicure (NASDAQ:XCUR - Get Free Report) last posted its quarterly earnings results on Friday, November 7th. The company reported ($0.39) earnings per share (EPS) for the quarter.
Wall Street Analysts Forecast Growth
Separately, Weiss Ratings reissued a "sell (d-)" rating on shares of Exicure in a report on Monday. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company has a consensus rating of "Sell".
Get Our Latest Analysis on XCUR
Exicure Company Profile
(
Get Free Report)
Exicure, Inc, an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
